18422462|t|Spectrum of adverse events after generic HAART in southern Indian HIV-infected patients.
18422462|a|To determine the incidence of clinically significant adverse events after long-term, fixed-dose, generic highly active antiretroviral therapy (HAART) use among HIV-infected individuals in South India, we examined the experiences of 3154 HIV-infected individuals who received a minimum of 3 months of generic HAART between February 1996 and December 2006 at a tertiary HIV care referral center in South India. The most common regimens were 3TC + d4T + nevirapine (NVP) (54.8%), zidovudine (AZT) + 3TC + NVP (14.5%), 3TC + d4T + efavirenz (EFV) (20.1%), and AZT + 3TC + EFV (5.4%). The most common adverse events and median CD4 at time of event were rash (15.2%; CD4, 285 cells/microL) and peripheral neuropathy (9.0% and 348 cells/microL). Clinically significant anemia (hemoglobin <7 g/dL) was observed in 5.4% of patients (CD4, 165 cells/microL) and hepatitis (clinical jaundice with alanine aminotransferase > 5 times upper limits of normal) in 3.5% of patients (CD4, 260 cells/microL). Women were significantly more likely to experience lactic acidosis, while men were significantly more likely to experience immune reconstitution syndrome (p < 0.05). Among the patients with 1 year of follow-up, NVP therapy was significantly associated with developing rash and d4T therapy with developing peripheral neuropathy (p < 0.05). Anemia and hepatitis often occur within 12 weeks of initiating generic HAART. Frequent and early monitoring for these toxicities is warranted in developing countries where generic HAART is increasingly available.
18422462	66	78	HIV-infected	DiseaseOrPhenotypicFeature	D015658
18422462	79	87	patients	OrganismTaxon	9606
18422462	249	261	HIV-infected	DiseaseOrPhenotypicFeature	D015658
18422462	326	338	HIV-infected	DiseaseOrPhenotypicFeature	D015658
18422462	528	531	3TC	ChemicalEntity	D019259
18422462	534	537	d4T	ChemicalEntity	D018119
18422462	540	550	nevirapine	ChemicalEntity	D019829
18422462	552	555	NVP	ChemicalEntity	D019829
18422462	566	576	zidovudine	ChemicalEntity	D015215
18422462	578	581	AZT	ChemicalEntity	D015215
18422462	585	588	3TC	ChemicalEntity	D019259
18422462	591	594	NVP	ChemicalEntity	D019829
18422462	604	607	3TC	ChemicalEntity	D019259
18422462	610	613	d4T	ChemicalEntity	D018119
18422462	616	625	efavirenz	ChemicalEntity	C098320
18422462	627	630	EFV	ChemicalEntity	C098320
18422462	645	648	AZT	ChemicalEntity	D015215
18422462	651	654	3TC	ChemicalEntity	D019259
18422462	657	660	EFV	ChemicalEntity	C098320
18422462	711	714	CD4	GeneOrGeneProduct	920
18422462	737	741	rash	DiseaseOrPhenotypicFeature	D005076
18422462	750	753	CD4	GeneOrGeneProduct	920
18422462	777	798	peripheral neuropathy	DiseaseOrPhenotypicFeature	D010523
18422462	851	857	anemia	DiseaseOrPhenotypicFeature	D000740
18422462	859	869	hemoglobin	GeneOrGeneProduct	3039
18422462	903	911	patients	OrganismTaxon	9606
18422462	913	916	CD4	GeneOrGeneProduct	920
18422462	940	949	hepatitis	DiseaseOrPhenotypicFeature	D056486
18422462	960	968	jaundice	DiseaseOrPhenotypicFeature	D007565
18422462	974	998	alanine aminotransferase	ChemicalEntity	D000410
18422462	1044	1052	patients	OrganismTaxon	9606
18422462	1054	1057	CD4	GeneOrGeneProduct	920
18422462	1078	1083	Women	OrganismTaxon	9606
18422462	1129	1144	lactic acidosis	DiseaseOrPhenotypicFeature	D000140
18422462	1152	1155	men	OrganismTaxon	9606
18422462	1201	1231	immune reconstitution syndrome	DiseaseOrPhenotypicFeature	D054019
18422462	1254	1262	patients	OrganismTaxon	9606
18422462	1289	1292	NVP	ChemicalEntity	D019829
18422462	1346	1350	rash	DiseaseOrPhenotypicFeature	D005076
18422462	1355	1358	d4T	ChemicalEntity	D018119
18422462	1383	1404	peripheral neuropathy	DiseaseOrPhenotypicFeature	D010523
18422462	1417	1423	Anemia	DiseaseOrPhenotypicFeature	D000740
18422462	1428	1437	hepatitis	DiseaseOrPhenotypicFeature	D056486
18422462	1535	1545	toxicities	DiseaseOrPhenotypicFeature	D064420
18422462	Positive_Correlation	D007565	D000410	Novel
18422462	Negative_Correlation	D015658	C098320	No
18422462	Negative_Correlation	D015658	D018119	No
18422462	Negative_Correlation	D015658	D019259	No
18422462	Negative_Correlation	D015658	D019829	No
18422462	Negative_Correlation	D015658	D015215	No
18422462	Positive_Correlation	D018119	D010523	Novel
18422462	Cotreatment	D018119	C098320	Novel
18422462	Cotreatment	D018119	D019829	Novel
18422462	Cotreatment	D019259	C098320	Novel
18422462	Cotreatment	D019259	D018119	Novel
18422462	Cotreatment	D019259	D019829	Novel
18422462	Positive_Correlation	D019829	D005076	Novel
18422462	Cotreatment	D015215	C098320	Novel
18422462	Cotreatment	D015215	D019259	Novel
18422462	Cotreatment	D015215	D019829	Novel